Diligence memo · auto-generated · as of July 3, 2026

Assurerx Health, Inc

Assurerx Health, Inc looks over-valued against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Assurerx Health, Inc operates in Other Health Care, based in MASON.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Assurerx Health, Inc has raised $51M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).

Largest single filing: $37M on 2014-12-19.

Most recent recorded round closed around 2014-12-19.

Valuation (modeled)modeled

Provath models Assurerx Health, Inc at approximately $828M (range $88M–$3.2B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Over-valued. Modeled value is 1.87× the median modeled value of Series B Other Health Care companies in 2013–2015 (85 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Historic cadence: a new round about every 32 months.

Last raise 11.5 yr ago; this sector typically re-raises about every 14 months.

Silent for over 3× the sector's normal cadence.

The last round stepped up 3.0× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 92% of Other Health Care peers (5377 compared).

Modeled value ranks above 96% of those peers.

Closest niche peers: Drynachan, Llc, Vistria SHC Holdings, LLC, Ebh Holding Company, Inc., Orthopediatrics Corp, IMRIS Inc..

Peoplefiled

19 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

Modeled above niche peers — valuation risk on entry.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.